ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
당뇨병 치료제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.3%로 성장할 전망이며, 905억 달러로 성장이 예측됩니다. 예측 기간에 예측되는 성장은 바이오시밀러 인슐린의 출현, 병용요법 및 고정용량 제제의 개발, 지속 글루코스 모니터링 및 클로즈드 루프 시스템에 대한 주목 증가, 당뇨병 예비군을 대상으로 한 인지도 향상 및 예방 프로그램 증가 등 여러 요인에 기인합니다. 이 기간에 주목해야 할 주요 동향은 지속적인 혈당 모니터링 및 스마트 약물 전달 시스템 통합, 디지털 환자 참여 플랫폼 채택, 웨어러블 약물 전달 장치의 시작, 펩타이드 또는 폴리머 기반 서방성 제형의 진보, 개인화 투여를 위한 파마 코유전체학 통합을 포함합니다.
당뇨병 환자 증가는 당뇨병 치료제 시장의 성장을 가속할 것으로 예측됩니다. 당뇨병 환자는 혈당(포도당)을 처리하는 신체 능력에 영향을 미치는 만성 질환인 당뇨병으로 진단된 환자를 말합니다. 당뇨병 환자 증가는 주로 건강에 해로운 식생활과 앉아있는 라이프 스타일이 비만과 인슐린 저항성을 유발합니다. 당뇨병 치료제는 1형 당뇨병과 2형 당뇨병 모두의 혈당 관리에 필수적이며 합병증 예방, 당 수준 안정화, 건강 전반 개선, 삶의 질 향상에 도움이 됩니다. 예를 들어, 2024년 6월 National Health Service의 보고에 따르면 2023년 비당뇨병성 고혈당 또는 당뇨병 예비군으로 진단받은 사람은 361만 5,330명으로 2022년 306만 5,825명에서 18% 증가했습니다. 따라서, 당뇨병 환자 증가는 당뇨병 치료제 시장의 확대를 견인하고 있습니다.
당뇨병 치료제 시장의 주요 기업은 혈당 조절을 개선하고 치료 요법을 단순화하며 환자의 어드히어런스를 높이기 위해 고정 비율 병용 요법과 같은 고급 치료법 개발에 주력하고 있습니다. 고정 비율 병용 요법은 두 개의 상보적인 항 당뇨병 약물을 단일 주사로 결합하여 당뇨병 관리에 효과적이고 편리한 접근법을 설명합니다. 예를 들어, 2024년 4월 프랑스 제약회사인 SanofiSA는 성인 2형 당뇨병과 비만증 환자를 대상으로 인슐린 글라진과 릭시세나티드의 1일 1회 투여 고정 비배합제인 솔리쿠아를 출시했습니다. Soliqua는 안정적인 공복 혈당 조절을 위한 장기간 작용하는 인슐린 글라진과 GLP-1 수용체 작용제인 릭시세나티드를 결합한 약물입니다. 이 조합은 포도당 의존성 인슐린 분비를 증가시키고, 글루카곤 생산을 억제하며, 위 배출을 늦추고 식후 혈당를 낮추어, 매일 종합적인 혈당 관리를 설명합니다. Soliqua 출시는 당뇨병 관리를 간소화하고, 혈당 조절을 개선하며, 매일 여러 번 주사할 필요성을 줄이고, 저혈당과 체중 증가와 같은 잠재적인 부작용을 최소화함으로써 환자의 어드레싱을 향상시키는 것을 목표로 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 당뇨병 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 당뇨병 치료제 시장 : 성장률 분석
세계의 당뇨병 치료제 시장 실적 : 규모 및 성장(2019-2024년)
세계의 당뇨병 치료제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 당뇨병 치료제 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 당뇨병 치료제 시장 : 약제 클래스별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
인슐린
비구아나이드
설포닐우레아
디펩티딜 펩티다아제(DPP)-4 억제제
나트륨-글루코오스 공수송체(SGLT)-2 억제제
글루카곤 유사 펩티드(GLP)-1 수용체 작용제
티아졸리딘디온
α-글루코시다아제 억제제
세계의 당뇨병 치료제 시장 : 배합 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
정제
주사
솔루션
겔
서방형 제제
세계의 당뇨병 치료제 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
경구
주사
흡입
세계의 당뇨병 치료제 시장 : 상태별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
1형 당뇨병
2형 당뇨병
세계의 당뇨병 치료제 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
전문 약국
세계의 당뇨병 치료제 시장 : 인슐린 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
속효형 인슐린
속효형 인슐린
중간형 인슐린
장시간 작용형 인슐린
혼합 인슐린
세계의 당뇨병 치료제 시장 : 비구아나이드 약 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
메트포르민 즉방성(IR)
메트포르민 서방형(ER)
세계의 당뇨병 치료제 시장 : 설포닐우레아약 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제1세대 설포닐우레아약
제2세대 설포닐우레아약
세계의 당뇨병 치료제 시장 : 디펩티딜펩티다아제(DPP)-4 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
시타글립틴
사그립틴
리나글립틴
알로글립틴
세계의 당뇨병 치료제 시장 : 나트륨-글루코오스 공수송체(SGLT)-2 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
카나글리플로진
다파글리플로진
엠파글리플로진
엘츠글리플로진
세계의 당뇨병 치료제 시장 : 글루카곤 유사 펩티드(GLP)-1 수용체 작용제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
엑세나티드
리라글루티드
듀라글루티드
세마글루티드
릭시세나티드
세계의 당뇨병 치료제 시장 : 티아졸리딘디온(TZD) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
피오글리타존
로시글리타존
세계의 당뇨병 치료제 시장 : α-글루코시다아제 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
아카르보스
미글리톨
제7장 지역별 및 국가별 분석
세계의 당뇨병 치료제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 당뇨병 치료제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
당뇨병 치료제 시장 : 경쟁 구도
당뇨병 치료제 시장 : 기업 프로파일
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
AstraZeneca plc
Abbott Laboratories
GSK plc
Medtronic plc
Eli Lilly and Company
Teva Pharmaceuticals Limited
Astellas Pharma Inc.
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Limited
Dr. Reddy's Laboratories
Cipla Limited
Lupin Limited
Takeda Pharmaceutical Company Limited
Biocon Limited
Glenmark Pharmaceuticals Limited
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
당뇨병 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
당뇨병 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
당뇨병 치료제 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Diabetes care drugs are medications used to manage blood glucose levels in individuals with diabetes mellitus, including type 1, type 2, and gestational diabetes. These drugs work by improving insulin production, enhancing insulin sensitivity, or reducing glucose absorption, with the primary goal of preventing complications by maintaining healthy blood sugar levels.
The primary drug classes in diabetes care include insulin, biguanides, sulfonylureas, dipeptidyl peptidase (DPP)-4 inhibitors, sodium-glucose co-transporter (SGLT)-2 inhibitors, glucagon-like peptide (GLP)-1 receptor agonists, thiazolidinediones, and alpha-glucosidase inhibitors. Insulin, a pharmaceutical version of the natural hormone, is administered through injection or inhalation to compensate for the body's insufficient production or utilization of insulin. These drugs are available in various formulations such as tablets, injections, solutions, gels, and extended-release formulations. They can be administered orally, by injection, or via inhalation, and are primarily used to manage Type 1 and Type 2 diabetes. These drugs are distributed through various channels, including hospital pharmacies and specialty pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The diabetes care drugs market research report is one of a series of new reports from The Business Research Company that provides diabetes care drugs market statistics, including the diabetes care drugs industry's global market size, regional shares, competitors with the diabetes care drugs market share, detailed diabetes care drugs market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes care drugs market. This diabetes care drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The diabetes care drugs market size has grown strongly in recent years. It will grow from $69.55 billion in 2024 to $73.48 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historic period can be attributed to several factors, including the rising global prevalence of diabetes, an increasing aging population, sedentary lifestyles, poor dietary habits, rising obesity rates, and the growing adoption of personalized medicine in diabetes care.
The diabetes care drugs market size is expected to see strong growth in the next few years. It will grow to $90.50 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth projected for the forecast period can be attributed to several factors, including the emergence of biosimilar insulins, the development of combination therapies and fixed-dose formulations, a growing focus on continuous glucose monitoring and closed-loop systems, and increasing awareness and prevention programs aimed at prediabetes. Key trends to watch during this period include the integration of continuous glucose monitoring with smart drug delivery systems, the adoption of digital patient engagement platforms, the rise of wearable drug delivery devices, advancements in peptide or polymer-based sustained-release formulations, and the integration of pharmacogenomics for personalized dosing.
The increasing number of diabetic patients is expected to drive the growth of the diabetes care drugs market. Diabetic patients are individuals diagnosed with diabetes mellitus, a chronic condition that affects the body's ability to process blood sugar (glucose). The rise in diabetes cases is mainly attributed to unhealthy diets and sedentary lifestyles, which contribute to obesity and insulin resistance. Diabetes care drugs are essential for managing blood glucose levels in both type 1 and type 2 diabetes, helping to prevent complications, stabilize sugar levels, improve overall health, and enhance the quality of life. For example, in June 2024, the National Health Service reported that 3,615,330 individuals were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, an 18% increase from 3,065,825 cases in 2022. Therefore, the growing number of diabetic patients is driving the expansion of the diabetes care drugs market.
Leading companies in the diabetes care drugs market are focusing on developing advanced treatments, such as fixed-ratio combination therapies, to improve glycemic control, simplify treatment regimens, and enhance patient adherence. Fixed-ratio combination therapies combine two complementary antidiabetic agents in a single injection, providing a more effective and convenient approach to managing diabetes. For instance, in April 2024, Sanofi SA, a France-based pharmaceutical company, launched Soliqua, a once-daily fixed-ratio combination of insulin glargine and lixisenatide for adults with type 2 diabetes and obesity. Soliqua combines long-acting insulin glargine for steady fasting glucose control with lixisenatide, a GLP-1 receptor agonist. This combination enhances glucose-dependent insulin secretion, suppresses glucagon production, and slows gastric emptying to reduce post-meal blood sugar levels, offering comprehensive daily glycemic management. The launch of Soliqua aims to simplify diabetes management, improve glycemic control, and increase patient adherence by reducing the need for multiple daily injections and minimizing potential side effects such as hypoglycemia and weight gain.
In December 2024, Lupin Limited, an India-based pharmaceutical company, acquired anti-diabetes trademarks from Boehringer Ingelheim International GmbH for an undisclosed amount. With this acquisition, Lupin now holds full trademark rights to GIBTULIO, GIBTULIO MET, and AJADUO, allowing the company to independently market these oral antidiabetic products across India and further expand its diabetes care portfolio. Boehringer Ingelheim International GmbH is a Germany-based pharmaceutical company, specializes in the manufacture of diabetes care drugs.
Major players in the diabetes care drugs market are Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GSK plc, Medtronic plc, Eli Lilly and Company, Teva Pharmaceuticals Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Cipla Limited, Lupin Limited, Takeda Pharmaceutical Company Limited, Biocon Limited, Glenmark Pharmaceuticals Limited, Insulet Corporation, Torrent Pharmaceuticals Ltd., Hanmi Pharmaceutical Limited, Hualan Biological, Wockhardt, Mitsubishi Tanabe Pharma, Gan & Lee Pharmaceuticals, DiogenX, Oramed Pharmaceuticals, and Apotex.
North America was the largest region in the diabetes care drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetes care drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the diabetes care drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The diabetes care drugs market consists of sales of oral antidiabetic drugs, non-insulin injectable drugs, and combination drugs. The market value includes the value of related goods sold by the service provider or contained within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Diabetes Care Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on diabetes care drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for diabetes care drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetes care drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Diabetes Care Drugs Market Characteristics
3. Diabetes Care Drugs Market Trends And Strategies
4. Diabetes Care Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Diabetes Care Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Diabetes Care Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Diabetes Care Drugs Market Growth Rate Analysis
5.4. Global Diabetes Care Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Diabetes Care Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Diabetes Care Drugs Total Addressable Market (TAM)
6. Diabetes Care Drugs Market Segmentation
6.1. Global Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Insulin
Biguanides
Sulfonylureas
Dipeptidyl Peptidase (DPP)-4 Inhibitors
Sodium-Glucose Co-Transporter (SGLT)-2 Inhibitors
Glucagon-Like Peptide (GLP)-1 Receptor Agonists
Thiazolidinediones
Alpha-Glucosidase Inhibitors
6.2. Global Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Injections
Solutions
Gels
Extended-Release Formulations
6.3. Global Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Inhalable
6.4. Global Diabetes Care Drugs Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diabetes Type 1
Diabetes Type 2
6.5. Global Diabetes Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies
6.6. Global Diabetes Care Drugs Market, Sub-Segmentation Of Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Long-acting insulin
Pre-mixed insulin
6.7. Global Diabetes Care Drugs Market, Sub-Segmentation Of Biguanides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metformin Immediate Release (IR)
Metformin Extended Release (ER)
6.8. Global Diabetes Care Drugs Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-generation sulfonylureas
Second-generation sulfonylureas
6.9. Global Diabetes Care Drugs Market, Sub-Segmentation Of Dipeptidyl Peptidase (DPP)-4 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
6.10. Global Diabetes Care Drugs Market, Sub-Segmentation Of Sodium-Glucose Co-Transporter (SGLT)-2 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Canagliflozin
Dapagliflozin
Empagliflozin
Ertugliflozin
6.11. Global Diabetes Care Drugs Market, Sub-Segmentation Of Glucagon-Like Peptide (GLP)-1 Receptor Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Exenatide
Liraglutide
Dulaglutide
Semaglutide
Lixisenatide
6.12. Global Diabetes Care Drugs Market, Sub-Segmentation Of Thiazolidinediones (TZDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pioglitazone
Rosiglitazone
6.13. Global Diabetes Care Drugs Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acarbose
Miglitol
7. Diabetes Care Drugs Market Regional And Country Analysis
7.1. Global Diabetes Care Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Diabetes Care Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Diabetes Care Drugs Market
8.1. Asia-Pacific Diabetes Care Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Diabetes Care Drugs Market
9.1. China Diabetes Care Drugs Market Overview
9.2. China Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Diabetes Care Drugs Market
10.1. India Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Diabetes Care Drugs Market
11.1. Japan Diabetes Care Drugs Market Overview
11.2. Japan Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Diabetes Care Drugs Market
12.1. Australia Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Diabetes Care Drugs Market
13.1. Indonesia Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Diabetes Care Drugs Market
14.1. South Korea Diabetes Care Drugs Market Overview
14.2. South Korea Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Diabetes Care Drugs Market
15.1. Western Europe Diabetes Care Drugs Market Overview
15.2. Western Europe Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Diabetes Care Drugs Market
16.1. UK Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Diabetes Care Drugs Market
17.1. Germany Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Diabetes Care Drugs Market
18.1. France Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Diabetes Care Drugs Market
19.1. Italy Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Diabetes Care Drugs Market
20.1. Spain Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Diabetes Care Drugs Market
21.1. Eastern Europe Diabetes Care Drugs Market Overview
21.2. Eastern Europe Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Diabetes Care Drugs Market
22.1. Russia Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Diabetes Care Drugs Market
23.1. North America Diabetes Care Drugs Market Overview
23.2. North America Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Diabetes Care Drugs Market
24.1. USA Diabetes Care Drugs Market Overview
24.2. USA Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Diabetes Care Drugs Market
25.1. Canada Diabetes Care Drugs Market Overview
25.2. Canada Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Diabetes Care Drugs Market
26.1. South America Diabetes Care Drugs Market Overview
26.2. South America Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Diabetes Care Drugs Market
27.1. Brazil Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Diabetes Care Drugs Market
28.1. Middle East Diabetes Care Drugs Market Overview
28.2. Middle East Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Diabetes Care Drugs Market
29.1. Africa Diabetes Care Drugs Market Overview
29.2. Africa Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Diabetes Care Drugs Market Competitive Landscape And Company Profiles
30.1. Diabetes Care Drugs Market Competitive Landscape
30.2. Diabetes Care Drugs Market Company Profiles
30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
31. Diabetes Care Drugs Market Other Major And Innovative Companies
31.1. AstraZeneca plc
31.2. Abbott Laboratories
31.3. GSK plc
31.4. Medtronic plc
31.5. Eli Lilly and Company
31.6. Teva Pharmaceuticals Limited
31.7. Astellas Pharma Inc.
31.8. Sun Pharmaceutical Industries Ltd.
31.9. Aurobindo Pharma Limited
31.10. Dr. Reddy's Laboratories
31.11. Cipla Limited
31.12. Lupin Limited
31.13. Takeda Pharmaceutical Company Limited
31.14. Biocon Limited
31.15. Glenmark Pharmaceuticals Limited
32. Global Diabetes Care Drugs Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Diabetes Care Drugs Market
34. Recent Developments In The Diabetes Care Drugs Market
35. Diabetes Care Drugs Market High Potential Countries, Segments and Strategies
35.1 Diabetes Care Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Diabetes Care Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Diabetes Care Drugs Market In 2029 - Growth Strategies
